NCT02362217View on ClinicalTrials.gov

A Study to Assess the Safety of HIV and Hep C Vaccine Candidates When Given Separately or in Combination

PHASE1CompletedINTERVENTIONAL
Enrollment

33

Participants

Timeline

Start Date

October 31, 2014

Primary Completion Date

August 31, 2016

Study Completion Date

October 31, 2017

Conditions
Hepatitis C InfectionHIV Infection
Interventions
BIOLOGICAL

AdCh3NSmut1

Genetic vaccine against Hepatitis C virus infection

BIOLOGICAL

MVA-NSmut

Genetic vaccine against Hepatitis C virus infection

BIOLOGICAL

ChAdV63.HIVconsv

Genetic vaccine against HIV-1 infection

BIOLOGICAL

MVA.HIVconsv

Genetic vaccine against HIV-1 infection

Trial Locations (1)

OX3 7LE

Centre for Clinical Vaccinology and Tropical Medicine, Oxford

Sponsors

Collaborators (1)

GlaxoSmithKline
All Listed Sponsors
collaborator

ReiThera Srl

INDUSTRY

collaborator

GlaxoSmithKline

INDUSTRY

lead

University of Oxford

OTHER

NCT02362217 - A Study to Assess the Safety of HIV and Hep C Vaccine Candidates When Given Separately or in Combination | Biotech Hunter | Biotech Hunter